This information may provide insights into the unfavorable prognosis associated with AML patients with FLT3-ITD mutations and wild-type NPM1 compared to those with both NPM1 and FLT3-ITD mutations [41]. This evidence concerns the gene NPM1 and acute myeloid leukemia.